Sopharma is also the largest shareholder in Momina Krepost AD, in which it controls 35.477%.
Sopharma recently acquired 2.33% of Lavena AD (via related parties), increasing its interest in it to 5.18%.
The executive director Ognyan Donev defined the acquisition as a portfolio type one, he pointed out that he knows personally and trusts Lavena's management.
It became clear last week that Sopharma has signed a contract with the Polish Natur Product Zdrovit for the establishment of a joint stock company.
This week the company announced its decision to list stock on the Warsaw Stock Exchange. If this happens Sopharma will be the first Bulgarian company to be listed on both BSE and another regulated market.
Stock price varied between 8.30 and 9.25 leva yesterday.